The latest funding rounds, like Ridge Biotechnologies’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New funding rounds, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Industry Trends
See who's moving and how much in your market
No credit card required Weekly funding digest
Ridge Biotechnologies raises $25 million in seed financing to enhance AI-enabled precision enzyme and drug design, led by Sutter Hill Ventures.
Ridge Biotechnologies has emerged from stealth with an oversubscribed $25 million in seed financing. The round was led by Sutter Hill Ventures, with participation from Overlap Holdings. The funding will support the rollout of its NativeLink and ProTrigger products. Ridge Bio aims to develop cutting-edge therapeutics using machine learning and bioengineering.
Company Information
Company
Ridge Biotechnologies
Location
Palo Alto, California, United States
About
Ridge Biotechnologies is a pioneering company focused on AI-enabled precision enzyme and targeted drug design. The company aims to revolutionize drug development through advanced machine learning and bioengineering techniques. Their innovative platform enables the design of therapeutics that address complex drug development challenges, promising safer and more precise medicines. Ridge Bio has launched products such as NativeLink and ProTrigger, enhancing therapeutic applications in antibody-drug conjugates.
Palo AltoBiotechnologyHealth CareArtificial Intelligence